Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Lundbeck Australia Pty Ltd

Sunday, 15 October, 2017



Rexulti group 02

October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1

The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1

REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.

Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.

Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.

1. REXULTI® Australian Approved Product Information.

Related Sponsored Contents

The risk of infection via surfaces and the new coronavirus

Whiteley Corporation is exploring improved hygiene and safe disinfectants through world best...

The importance of surface cleaning

The rate of healthcare-associated infections can be significantly reduced through effective...

When cleanliness matters, knowledge is power

In these times, it has become more evident than ever that cleanliness leads to curbing the spread...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd